Chester Kao

5PUBLICATIONS
49CO-AUTHORS
Molecular targetsPredictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (5)

|Jun 26, 2026
Peripheral Th17 immune signature associates with excellent response to anti-PD1/anti-PD-L1 therapy across solid tumors.

|Sep 15, 2025
Immune Activation Signatures Associated with Fatigue in Cancer Patients Undergoing Immune Checkpoint Inhibitor Therapy.

Howard L Li, Soren Charmsaz, Mari Nakazawa

|Mar 27, 2025
Anti-CTLA4 Therapy Leads to Early Expansion of a Peripheral Th17 Population and Induction of Th1 Cytokines.

Mari Nakazawa, Soren Charmsaz, Elsa Hallab

|Jul 24, 2023
Salvage Ipilimumab plus Nivolumab after Anti-PD-1/PD-L1 Therapy in Advanced Hepatocellular Carcinoma.

Stephanie L Alden, Mir Lim, Chester Kao

|Nov 30, 2020
An Illustrative Case of Combination Cabozantinib/Nivolumab for Progressive Metastatic Renal Cell Carcinoma (mRCC).

Chester Kao, Daniel J George, Tian Zhang

Pageof 1

Frequent Collaborators

4 joint publications

Marina Baretti

4 joint publications

Won Jin Ho

4 joint publications

Mark Yarchoan

3 joint publications

Evan J Lipson